Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Aloe vera inner gel (not the latex) has a reasonable safety profile at normal supplemental doses. The latex (outer leaf) contains anthraquinones with laxative and genotoxic potential. Even the inner gel at high doses may cause electrolyte imbalances and GI cramping. It may interact with digoxin, diuretics, and anticoagulants. Avoid in pregnancy.
Biological and Chemical Classification
- Scientific Name
- Aloe barbadensis
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Aloe Vera Leaf Gel indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:23
Evidence Distribution
-
Observational / other LOW evidence YELLOWBiocompatibility and photothermal efficiency of silver palladium (AgPd NPs) and gold palladium (AuPd NP) bimetallic nanoparticles synthesized using Aloe barbadensis Linn. leaf… ↗Lakkakula JR et al.. Biocompatibility and photothermal efficiency of silver palladium (AgPd NPs) and gold palladium (AuPd NP) bimetallic nanoparticles synthesized using Aloe barbadensis Linn. leaf gel.. Cytotechnology. 2026. PMID:41835402.PMID 41835402 ↗Journal CytotechnologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41835402/
-
Observational / other LOW evidence YELLOWDraft genome sequence of Enterobacter sp. I4, an endophytic bacterium isolated from Aloe barbadensis Miller. ↗Nchabeleng MM et al.. Draft genome sequence of Enterobacter sp. I4, an endophytic bacterium isolated from Aloe barbadensis Miller.. Microbiol Resour Announc. 2026. PMID:41823384.PMID 41823384 ↗Journal Microbiol Resour AnnouncYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41823384/
-
Observational / other LOW evidence YELLOWEvaluation and modulation of bactericidal potential of different antibacterial agents against bacterial pathogens from conjunctivitis infections. ↗Arshad S et al.. Evaluation and modulation of bactericidal potential of different antibacterial agents against bacterial pathogens from conjunctivitis infections.. J Ophthalmic Inflamm Infect. 2026. PMID:41792584.PMID 41792584 ↗Journal J Ophthalmic Inflamm InfectYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41792584/
-
Observational / other LOW evidence YELLOWTherapeutic potential of Aloe vera in diabetes mellitus treatment: an update. ↗Adil M et al.. Therapeutic potential of Aloe vera in diabetes mellitus treatment: an update.. Saudi Pharm J. 2026. PMID:41779103.PMID 41779103 ↗Journal Saudi Pharm JYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41779103/
-
Observational / other LOW evidence YELLOWComparative In Vitro Evaluation of the Antimicrobial Efficacy of Tulsi, Triphala, and Aloe Vera against Streptococcus mutans Relative to Chlorhexidine. ↗Singh D et al.. Comparative In Vitro Evaluation of the Antimicrobial Efficacy of Tulsi, Triphala, and Aloe Vera against Streptococcus mutans Relative to Chlorhexidine.. Int J Clin Pediatr Dent. 2025. PMID:41552029.PMID 41552029 ↗Journal Int J Clin Pediatr DentYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41552029/
-
Observational / other LOW evidence YELLOWPlant-Mediated Synthesis of Nickel-Doped Cobalt Oxide/Reduced Graphene Oxide Nanocomposites for Combined Antibacterial Activity and EMI Shielding. ↗David DA et al.. Plant-Mediated Synthesis of Nickel-Doped Cobalt Oxide/Reduced Graphene Oxide Nanocomposites for Combined Antibacterial Activity and EMI Shielding.. ACS Omega. 2025. PMID:41427189.PMID 41427189 ↗Journal ACS OmegaYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41427189/
-
Observational / other LOW evidence YELLOWPhytogenic Silver Nanoparticles Derived from Ricinus communis and Aloe barbadensis: Synthesis, Characterization, and Evaluation of Biomedical Potential. ↗Ahsan A et al.. Phytogenic Silver Nanoparticles Derived from Ricinus communis and Aloe barbadensis: Synthesis, Characterization, and Evaluation of Biomedical Potential.. Bioengineering (Basel). 2025. PMID:41301228.PMID 41301228 ↗Journal Bioengineering (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41301228/
-
Observational / other LOW evidence YELLOWComparative Clinical and Radiographic Evaluation of Three Different Herbal Extracts in Combination with Calcium Hydroxide as Obturating Materials in Primary Teeth: An… ↗Amudala N et al.. Comparative Clinical and Radiographic Evaluation of Three Different Herbal Extracts in Combination with Calcium Hydroxide as Obturating Materials in Primary Teeth: An In Vivo Study.. Int J Clin Pediatr Dent. 2025. PMID:41041409.PMID 41041409 ↗Journal Int J Clin Pediatr DentYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41041409/
-
Observational / other LOW evidence YELLOWClinical Evidence of Traditional Medicines in Modulating the Immune Response and Diabetic Wound Healing. ↗Dwivedi J et al.. Clinical Evidence of Traditional Medicines in Modulating the Immune Response and Diabetic Wound Healing.. Curr Top Med Chem. 2025. PMID:40676793.PMID 40676793 ↗Journal Curr Top Med ChemYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40676793/
-
Observational / other LOW evidence YELLOWNature's Remedy: A Comprehensive Review Exploring Herbal Treatments and Natural Approaches for Preventing Acne Vulgaris. ↗Shingari M et al.. Nature's Remedy: A Comprehensive Review Exploring Herbal Treatments and Natural Approaches for Preventing Acne Vulgaris.. Recent Adv Antiinfect Drug Discov. 2025. PMID:40662556.PMID 40662556 ↗Journal Recent Adv Antiinfect Drug DiscovYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40662556/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Aloe Vera Leaf Gel. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Aloe Vera Leaf Gel
A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.